Telo Genomics CorpTSXV:TELOView on OTCQB
- LAST PRICE0.1200
- TODAY'S CHANGE (%)0.0050 (4.3478%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1200 / 0.1150
- Day Range
- 52 Week Range
- Volume6,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TELO |
|---|---|---|
| 10:26 ET | 3000 | 0.12 |
| 10:31 ET | 3000 | 0.12 |
Nov 19, 2024
Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON), from 8:46AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:46AM ET on Tuesday Nov 19, 2024 by Dow Jones
Oct 30, 2024
Telo Genomics Expands its Strategic Collaboration with Mayo Clinic, from 8:47AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:47AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Telo Genomics Corp | 8.6M | -3.2x | --- |
XORTX Therapeutics Inc | 5.5M | -37.3x | --- |
Marvel Biosciences Corp | 7.2M | -3.2x | --- |
Hemostemix Inc | 10.5M | -4.0x | --- |
Glow Lifetech Corp | 6.1M | -1.6x | --- |
Quest Pharmatech Inc | 5.9M | 0.4x | --- |
Company Information
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.
Contact Information
- Headquarters
- Mars Centre, 101 College St Suite 200TORONTO, ON, Canada M5G 1L7
- Phone
- 416-673-8487
- Fax
- 204-582-0922
Executives
- Chairman of the Board
- Guido Baechler
- President, Chief Technology Officer
- Sherif Louis
- Interim Chief Executive Officer, Director, Chair of the Clinical and Scientific Advisory Board
- Sabine Mai
- Chief Financial Officer
- Christopher Ross
- Independent Director
- Ron Mcglennen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 74.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.04 |
Book Value | $0.01 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
